Switch theme
Sign up to access all valuation multiples
RxSight Inc is a commercial-stage medical technology company dedicated towards improving the vision of patients following cataract surgery. It offers intraocular lens technology that enables doctors to customize and optimize visual acuity for patients after cataract surgery. The company operates and manages its business in one reportable segment, the research and development, manufacture and sale of light adjustable lenses and related capital equipment.
1997
498
LTM Revenue $151M
LTM EBITDA -$28.0M
$404M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
RxSight has a last 12-month revenue (LTM) of $151M and a last 12-month EBITDA of -$28.0M.
In the most recent fiscal year, RxSight achieved revenue of $140M and an EBITDA of -$23.8M.
RxSight expects next 12-month revenue of XXX and NTM EBITDA of XXX
See RxSight valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $151M | XXX | $140M | XXX | XXX | XXX |
| Gross Profit | $108M | XXX | $98.9M | XXX | XXX | XXX |
| Gross Margin | 72% | XXX | 71% | XXX | XXX | XXX |
| EBITDA | -$28.0M | XXX | -$23.8M | XXX | XXX | XXX |
| EBITDA Margin | -19% | XXX | -17% | XXX | XXX | XXX |
| EBIT | -$34.2M | XXX | -$36.9M | XXX | XXX | XXX |
| EBIT Margin | -23% | XXX | -26% | XXX | XXX | XXX |
| Net Profit | -$26.6M | XXX | -$27.5M | XXX | XXX | XXX |
| Net Margin | -18% | XXX | -20% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, RxSight's stock price is $15.
RxSight has current market cap of $621M, and EV of $404M.
See RxSight trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $404M | $621M | XXX | XXX | XXX | XXX | $-0.70 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, RxSight has market cap of $621M and EV of $404M.
RxSight's trades at 2.9x EV/Revenue multiple, and -17.0x EV/EBITDA.
Equity research analysts estimate RxSight's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
RxSight has a P/E ratio of -23.4x.
See valuation multiples for RxSight and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $621M | XXX | $621M | XXX | XXX | XXX |
| EV (current) | $404M | XXX | $404M | XXX | XXX | XXX |
| EV/Revenue | 2.7x | XXX | 2.9x | XXX | XXX | XXX |
| EV/EBITDA | -14.4x | XXX | -17.0x | XXX | XXX | XXX |
| EV/EBIT | -11.8x | XXX | -11.0x | XXX | XXX | XXX |
| EV/Gross Profit | 3.7x | XXX | n/a | XXX | XXX | XXX |
| P/E | -23.4x | XXX | -22.6x | XXX | XXX | XXX |
| EV/FCF | -19.6x | XXX | -18.0x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialRxSight's last 12 month revenue growth is 20%
RxSight's revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $0.3M for the same period.
RxSight's rule of 40 is -26% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
RxSight's rule of X is 32% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for RxSight and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 20% | XXX | 20% | XXX | XXX | XXX |
| EBITDA Margin | -19% | XXX | -17% | XXX | XXX | XXX |
| EBITDA Growth | -39% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -26% | XXX | 3% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 32% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.3M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.3M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 25% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 97% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Philips | XXX | XXX | XXX | XXX | XXX | XXX |
| Perspective Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| SmartVest | XXX | XXX | XXX | XXX | XXX | XXX |
| InfuSystem | XXX | XXX | XXX | XXX | XXX | XXX |
| Myomo | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
RxSight acquired XXX companies to date.
Last acquisition by RxSight was XXXXXXXX, XXXXX XXXXX XXXXXX . RxSight acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was RxSight founded? | RxSight was founded in 1997. |
| Where is RxSight headquartered? | RxSight is headquartered in United States of America. |
| How many employees does RxSight have? | As of today, RxSight has 498 employees. |
| Who is the CEO of RxSight? | RxSight's CEO is Dr. Ron Kurtz, M.D.. |
| Is RxSight publicy listed? | Yes, RxSight is a public company listed on NAS. |
| What is the stock symbol of RxSight? | RxSight trades under RXST ticker. |
| When did RxSight go public? | RxSight went public in 2021. |
| Who are competitors of RxSight? | Similar companies to RxSight include e.g. Philips, Perspective Therapeutics, SmartVest, InfuSystem. |
| What is the current market cap of RxSight? | RxSight's current market cap is $621M |
| What is the current revenue of RxSight? | RxSight's last 12 months revenue is $151M. |
| What is the current revenue growth of RxSight? | RxSight revenue growth (NTM/LTM) is 20%. |
| What is the current EV/Revenue multiple of RxSight? | Current revenue multiple of RxSight is 2.7x. |
| Is RxSight profitable? | Yes, RxSight is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of RxSight? | RxSight's last 12 months EBITDA is -$28.0M. |
| What is RxSight's EBITDA margin? | RxSight's last 12 months EBITDA margin is -19%. |
| What is the current EV/EBITDA multiple of RxSight? | Current EBITDA multiple of RxSight is -14.4x. |
| What is the current FCF of RxSight? | RxSight's last 12 months FCF is -$20.6M. |
| What is RxSight's FCF margin? | RxSight's last 12 months FCF margin is -14%. |
| What is the current EV/FCF multiple of RxSight? | Current FCF multiple of RxSight is -19.6x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
